• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma.术前血清CA19-9水平是肝门部胆管癌切除患者的独立预后因素。
Int J Clin Exp Pathol. 2014 Oct 15;7(11):7890-8. eCollection 2014.
2
Elevated perioperative serum CA 19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma.术前血清 CA 19-9 水平升高是可切除胆管癌患者生存不良的独立预测因素。
J Surg Oncol. 2014 Sep;110(4):422-9. doi: 10.1002/jso.23666. Epub 2014 Jun 2.
3
Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma?术前和术后CA19-9水平能否预测可切除肝门部胆管癌患者的生存及早期复发情况?
Oncotarget. 2017 Jul 11;8(28):45335-45344. doi: 10.18632/oncotarget.17336.
4
Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases.肝门部胆管癌门静脉切除肝切除术:52例连续病例分析
Ann Surg. 2003 Nov;238(5):720-7. doi: 10.1097/01.sla.0000094437.68038.a3.
5
The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases.门静脉切除对肝门部胆管癌预后的影响:305 例多机构分析。
Cancer. 2012 Oct 1;118(19):4737-47. doi: 10.1002/cncr.27492. Epub 2012 Mar 13.
6
[Biopathological characteristics of hilar cholangiocarcinoma and the clinical significance].肝门部胆管癌的生物病理学特征及临床意义
Zhonghua Wai Ke Za Zhi. 2009 Aug 1;47(15):1162-6.
7
Survival analysis of intrahepatic cholangiocarcinoma after resection.肝内胆管癌切除术后的生存分析。
Ann Surg Oncol. 2010 Jul;17(7):1823-30. doi: 10.1245/s10434-010-0938-y. Epub 2010 Feb 18.
8
Surgical Indication for Advanced Intrahepatic Cholangiocarcinoma According to the Optimal Preoperative Carbohydrate Antigen 19-9 Cutoff Value.根据最佳术前糖类抗原19-9临界值确定晚期肝内胆管癌的手术指征
World J Surg. 2018 Oct;42(10):3331-3340. doi: 10.1007/s00268-018-4605-y.
9
Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer.CA19-9 对胆道癌切除术后患者的预后价值。
Br J Surg. 2017 Feb;104(3):267-277. doi: 10.1002/bjs.10415. Epub 2017 Jan 4.
10
The preoperative scoring system combining neutrophil/lymphocyte ratio and CA19-9 predicts the long-term prognosis of intrahepatic cholangiocarcinoma patients undergoing curative liver resection.中性粒细胞/淋巴细胞比值与 CA19-9 联合术前评分系统预测行根治性肝切除术的肝内胆管细胞癌患者的长期预后。
BMC Cancer. 2024 Sep 5;24(1):1106. doi: 10.1186/s12885-024-12819-0.

引用本文的文献

1
Albumin-bilirubin (ALBI) and Platelet-ALBI (PALBI) Grades: Novel Prognostic Factors for Cholangiocellular Carcinoma.白蛋白-胆红素(ALBI)和血小板-ALBI(PALBI)分级:胆管细胞癌的新型预后因素。
In Vivo. 2025 Sep-Oct;39(5):2976-2985. doi: 10.21873/invivo.14098.
2
Systematic Review of Preoperative Prognostic Biomarkers in Perihilar Cholangiocarcinoma.肝门部胆管癌术前预后生物标志物的系统评价
Cancers (Basel). 2024 Feb 7;16(4):698. doi: 10.3390/cancers16040698.
3
Molecular Biomarkers in Cholangiocarcinoma: Focus on Bile.胆管癌中的分子生物标志物:聚焦于胆汁。
Curr Top Med Chem. 2024;24(8):722-736. doi: 10.2174/0115680266290367240130054142.
4
Understanding the Clinical Significance of MUC5AC in Biliary Tract Cancers.了解MUC5AC在胆道癌中的临床意义。
Cancers (Basel). 2023 Jan 9;15(2):433. doi: 10.3390/cancers15020433.
5
Vascular invasion and lymph node metastasis mediate the effect of CA242 on prognosis in hilar cholangiocarcinoma patients after radical resection.血管侵犯和淋巴结转移介导了CA242对肝门部胆管癌患者根治性切除术后预后的影响。
Front Oncol. 2022 Dec 12;12:1071439. doi: 10.3389/fonc.2022.1071439. eCollection 2022.
6
Development and Validation of a Prognostic Model to Predict Recurrence-Free Survival After Curative Resection for Perihilar Cholangiocarcinoma: A Multicenter Study.预测肝门部胆管癌根治性切除术后无复发生存的预后模型的开发与验证:一项多中心研究
Front Oncol. 2022 Apr 21;12:849053. doi: 10.3389/fonc.2022.849053. eCollection 2022.
7
Prognostic and Predictive Molecular Markers in Cholangiocarcinoma.胆管癌的预后和预测分子标志物
Cancers (Basel). 2022 Feb 17;14(4):1026. doi: 10.3390/cancers14041026.
8
Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?肝胆癌中的生物标志物:在临床实践中有哪些有用的?
Cancers (Basel). 2021 May 30;13(11):2708. doi: 10.3390/cancers13112708.
9
Prognostic Impact of Perioperative CA19-9 Levels in Patients with Resected Perihilar Cholangiocarcinoma.围手术期CA19-9水平对肝门周围胆管癌切除患者的预后影响
J Clin Med. 2021 Mar 24;10(7):1345. doi: 10.3390/jcm10071345.
10
Prognostic factors of resectable perihilar cholangiocarcinoma: a systematic review and meta-analysis of high-quality studies.可切除性肝门部胆管癌的预后因素:高质量研究的系统评价与荟萃分析
Ther Adv Gastrointest Endosc. 2021 Feb 10;14:2631774521993065. doi: 10.1177/2631774521993065. eCollection 2021 Jan-Dec.

本文引用的文献

1
Aggressive surgical resection for hilar cholangiocarcinoma: is it justified? Audit of a single center's experience.肝门部胆管癌的积极手术切除:是否合理?单中心经验的审计
Am J Surg. 2008 Aug;196(2):160-9. doi: 10.1016/j.amjsurg.2007.07.033. Epub 2008 May 7.
2
Radiation therapy, chemotherapy and chemoradiation in hilar cholangiocarcinoma.肝门部胆管癌的放射治疗、化学疗法和放化疗。
HPB (Oxford). 2005;7(4):278-82. doi: 10.1080/13651820500373028.
3
Radical surgery for hilar cholangiocarcinoma.肝门部胆管癌根治性手术
Eur J Surg Oncol. 2008 Mar;34(3):263-71. doi: 10.1016/j.ejso.2007.09.024. Epub 2007 Nov 26.
4
Prognostic relevance of carbohydrate antigen 19-9 levels in patients with advanced biliary tract cancer.糖类抗原19-9水平在晚期胆管癌患者中的预后相关性
Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2097-100. doi: 10.1158/1055-9965.EPI-07-0155.
5
Major hepatectomy for hilar cholangiocarcinoma type 3 and 4: prognostic factors and longterm outcomes.3型和4型肝门部胆管癌的扩大肝切除术:预后因素及长期疗效
J Am Coll Surg. 2007 Feb;204(2):250-60. doi: 10.1016/j.jamcollsurg.2006.10.028. Epub 2006 Dec 27.
6
Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma.新辅助放化疗及肝移植治疗不可切除肝门部胆管癌后疾病复发的预测因素
Transplantation. 2006 Dec 27;82(12):1703-7. doi: 10.1097/01.tp.0000253551.43583.d1.
7
Is a raised CA 19-9 level diagnostic for a cholangiocarcinoma in patients with no history of sclerosing cholangitis ?对于无硬化性胆管炎病史的患者,CA 19-9水平升高对胆管癌有诊断意义吗?
Dig Surg. 2006;23(5-6):319-24. doi: 10.1159/000098014. Epub 2006 Dec 14.
8
Predictive factors for prognosis of hilar cholangiocarcinoma: postresection radiotherapy improves survival.肝门部胆管癌预后的预测因素:术后放疗可提高生存率。
Eur J Surg Oncol. 2007 Mar;33(2):202-7. doi: 10.1016/j.ejso.2006.09.033. Epub 2006 Nov 7.
9
One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality.对肝门部胆管癌进行的连续102例肝胆切除术,死亡率为零。
Ann Surg. 2006 Aug;244(2):240-7. doi: 10.1097/01.sla.0000217605.66519.38.
10
Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma.围手术期CA19-9水平可预测可切除胰腺腺癌患者的分期及生存情况。
J Clin Oncol. 2006 Jun 20;24(18):2897-902. doi: 10.1200/JCO.2005.05.3934.

术前血清CA19-9水平是肝门部胆管癌切除患者的独立预后因素。

Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma.

作者信息

Cai Wen-Ke, Lin Jia-Ji, He Gong-Hao, Wang Hua, Lu Jun-Hua, Yang Guang-Shun

机构信息

Department of Cardio-Thoracic Surgery, Kunming General Hospital of Chengdu Military Region Kunming, China.

Department of Neurology, Tangdu Hospital of Fourth Military Medical University Xi'an, China.

出版信息

Int J Clin Exp Pathol. 2014 Oct 15;7(11):7890-8. eCollection 2014.

PMID:25550829
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4270533/
Abstract

To investigate the appropriate cutoff point of CA19-9 for prognosis and other potential prognostic factors that may affect survival of patients with hilar cholangiocarcinoma (HC) after radical surgery. 168 patients who had undergone radical surgery for hilar cholangiocarcinoma and resultant macroscopic curative resection (R0 and R1) were discreetly selected for analyses. Categorized versions were used in univariate model to determine the appropriate cutoff point of CA19-9. CA19-9 and other clinicopathologic factors were analyzed for influence on survival by univariate and multivariate methods. The strongest univariate predictor among the categorized preoperative CA19-9 measures was CA19-9 less than 150 IU/L (P = 0.000). In univariate analysis, tumor size, Bismuth-Corlette classification, portal vein invasion, Lymph node metastasis, resection margin and preoperative CA19-9 levels were identified as significant prognostic factors. In multivariable analysis, lymph node metastasis, resection margin and preoperative CA19-9 levels were independent prognostic factors. our results demonstrated that preoperative CA19-9 levels was also an independent prognostic factor for hilar cholangiocarcinoma, and the most discriminative cutoff point of CA19-9 for prognosis proved to be at 150 U/ml.

摘要

为研究肝门部胆管癌(HC)根治性手术后CA19-9用于预后评估的合适临界值以及其他可能影响患者生存的潜在预后因素。谨慎选取168例行肝门部胆管癌根治性手术且获得宏观治愈性切除(R0和R1)的患者进行分析。在单因素模型中使用分类变量来确定CA19-9的合适临界值。采用单因素和多因素方法分析CA19-9及其他临床病理因素对生存的影响。术前CA19-9分类测量中最强的单因素预测指标是CA19-9低于150 IU/L(P = 0.000)。在单因素分析中,肿瘤大小、Bismuth-Corlette分型、门静脉侵犯、淋巴结转移、切缘及术前CA19-9水平被确定为显著预后因素。在多因素分析中,淋巴结转移、切缘及术前CA19-9水平是独立预后因素。我们的结果表明,术前CA19-9水平也是肝门部胆管癌的独立预后因素,且CA19-9用于预后评估的最具鉴别力的临界值为150 U/ml。